GLN-APREMILAST
Identification of Gln-Apremilast
| No description |
Google image searchProduct monograph
Active ingredient
apremilast, 30 MG
DIN: 02518910
Dosage form(s): TABLET
Route(s) of administration: ORAL
Schedule: Prescription
Company: GLENMARK PHARMACEUTICALS CANADA INC.
Date: 14-NOV-2022
ATC:
- L04 — IMMUNOSUPPRESSANTS (ATC, ATC/DDD, )
- L04A — IMMUNOSUPPRESSANTS (ATC, ATC/DDD)
- L04AA — Selective immunosuppressants (ATC, ATC/DDD)
- L04AA32 — APREMILAST (ATC/DDD)
Pharmaceutical standard: MFR
